Kepler Cheuvreux Suisse SA Raises Holdings in Pfizer Inc. $PFE

Kepler Cheuvreux Suisse SA boosted its position in Pfizer Inc. (NYSE:PFE) by 21.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 696,069 shares of the biopharmaceutical company’s stock after purchasing an additional 122,385 shares during the quarter. Pfizer comprises approximately 1.3% of Kepler Cheuvreux Suisse SA’s investment portfolio, making the stock its 25th largest position. Kepler Cheuvreux Suisse SA’s holdings in Pfizer were worth $19,546,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Horizon Financial Services LLC grew its holdings in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the fourth quarter worth about $26,000. YANKCOM Partnership acquired a new position in Pfizer during the fourth quarter worth about $28,000. HFM Investment Advisors LLC grew its stake in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. grew its stake in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $24.29 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company has a market capitalization of $138.45 billion, a PE ratio of 18.54 and a beta of 0.35. The firm’s 50-day moving average is $25.63 and its two-hundred day moving average is $26.23. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the firm earned $0.92 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 131.30%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Tuesday, June 23rd. CICC Research assumed coverage on Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Morgan Stanley upped their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.